Plain-English translation of NCT06145633 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a drug taken by mouth each day, can help improve how well a targeted cancer treatment called 177Lu-PSMA-617 works for men with advanced prostate cancer. The cancer being treated has become resistant to standard hormone-blocking drugs and has spread to other parts of the body. Researchers believe that might help the targeted treatment reach and destroy more cancer cells.
Some men with advanced prostate cancer don't respond well enough to the targeted treatment alone, even when it is used correctly. This trial exists to see whether adding this medication before treatment might help make the cancer treatment more effective for patients whose cancer has specific characteristics that make it harder to treat.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for 28 days, then have imaging scans to see how your cancer is responding. If appropriate, you would then receive the targeted cancer treatment intravenously on the first day of each 6-week cycle, for up to 6 cycles total. Throughout the trial, you would have regular CT scans, bone scans, PET scans, and blood tests to monitor your health and how well the treatment is working. After treatment ends, you would return for follow-up visits every 8 weeks for 6 months, then every 12 weeks for up to 2 years.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States